Re-appraisal of N2 disease by lymphatic drainage pattern for non-small-cell lung cancers: By terms of nodal stations, zones, chains, and a composite

被引:13
作者
Zheng, Hui [1 ]
Wang, Lin-mao [1 ]
Bao, Fang [1 ]
Jiang, Ge-ning [1 ]
Xie, Hui-kang [2 ]
Ding, Jia-an [1 ]
Hu, Xue-fei [1 ]
Chen, Chang [1 ]
机构
[1] Tongji Univ, Surg Shanghai Pulm Hosp, Dept Gen Thorac, Sch Med, Shanghai 200433, Peoples R China
[2] Tongji Univ, Shanghai Pulm Hosp, Dept Pathol, Sch Med, Shanghai 200433, Peoples R China
关键词
Non-small-cell lung cancer; TNM classification; N2; stage; Lymphadenectomy; Lymphatic metastasis; Prognosis; PROGNOSTIC-FACTORS; INTERNATIONAL ASSOCIATION; NODES; METASTASIS; SURVIVAL; NUMBER; CLASSIFICATION; CHEMOTHERAPY; INVOLVEMENT;
D O I
10.1016/j.lungcan.2011.03.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: N2 non-small-cell lung cancer (NSCLC) is a heterogeneous disease with an extremely wide range of 5-year survival rates. A composite method of sub-classification for N2 is likely to provide a more accurate method to more finely differentiate prognosis of N2 disease. Methods: A total of 720 pN2 (T1-4N2M0) NSCLC cases were enrolled in our retrospective analysis of the proposed composite method. Survival rates were respectively calculated according to the N2 stratification methods: singly by "nodal stations", "nodal zones", or "nodal chains", or by combination of all three. Statistical analysis was carried out by Kaplan-Meier and Cox regression models. Results: A total of 10,199 lymph nodes (8059 mediastinal; 2140 hilar and intra-lobar) were removed. By nodal station, there were 173 cases of single-station involvement and 547 multi-stations. By nodal zone, there were 413 single-zone involvement and 307 with multiple zones. By nodal chain, there were 311 cases with single-chain and 409 multi-chain involvements. The overall 5-year survival was 20% and median survival time was 27.52 months. The 5-year survival was significantly better for cases of single-zone involvement, as compared to multi-zones (29% vs. 6%, p < 0.0001). The 5-year survival rates of single- and multi-chains involvement were 36% and 8%, respectively (p < 0.0001). When taking all of the above grouping methods into consideration, the N2 disease state could be further sub-classified into two subgroups with respective survival rates of 36% and 7% (p < 0.0001). Subgroup I was composed of individuals with single-chain involvement and having either one or two station metastasis; individuals with any other metastasis combinations formed Subgroup II. Multivariate analysis revealed that the composite sub-classification method, number of positive lymph nodes, ratio of nodal metastasis, and pT information were the most important risk factors of 5-year survival. Conclusions: By combining the three N2 stratification methods based on "stations", "zones", and "chains" into one composite method, prognosis prediction was more accurate for N2 NSCLC disease. Single nodal chain involvement, which may be either one or two nodal stations metastasis, is associated with best outcome for pN2 patients. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:497 / 503
页数:7
相关论文
共 50 条
  • [21] Skip mediastinal nodal metastases in the Ilia/N2 non-small cell lung cancer
    Ilic, Nenad
    Petricevic, Ante
    Arar, Dragan
    Kotarac, Slavica
    Banovic, Josip
    Ric, Nives Frleta
    Tripkovic, Andro
    Grandic, Leo
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (11) : 1018 - 1021
  • [22] The N2 paradox: similar outcomes of pre- and postoperatively identified single-zone N2a positive non-small-cell lung cancer
    Tsitsias, Thomas
    Boulemden, Anas
    Ang, Keng
    Nakas, Apostolos
    Waller, David A.
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2014, 45 (05) : 882 - 887
  • [23] Clinical Predictors of Persistent Mediastinal Nodal Disease After Induction Therapy for Stage IIIA N2 Non-Small Cell Lung Cancer
    Kamel, Mohamed K.
    Rahouma, Mohamed
    Ghaly, Galal
    Nasar, Abu
    Port, Jeffrey L.
    Stiles, Brendon M.
    Nguyen, Andrew B.
    Altorki, Nasser K.
    Lee, Paul C.
    ANNALS OF THORACIC SURGERY, 2017, 103 (01) : 281 - 286
  • [24] Five-year survival analysis and prognostic factors in patients operated on for non-small cell lung cancer with N2 disease
    Lochowski, Mariusz
    Lochowska, Barbara
    Rebowski, Marek
    Brzezinski, Daniel
    Cieslik-Wolski, Bartosz
    Kozak, Jozef
    JOURNAL OF THORACIC DISEASE, 2018, 10 (06) : 3180 - 3186
  • [25] Neoadjuvant Chemotherapy With Docetaxel-Cisplatin in Patients With Stage III N2 Non-Small-Cell Lung Cancer
    Liao, Wei-Yu
    Chen, Jin-Hsin
    Wu, Muzo
    Shih, Jin-Yuan
    Chen, Kuan-Yuh
    Ho, Chao-Chi
    Yang, James Chih-Hsin
    Yu, Chong-Jen
    CLINICAL LUNG CANCER, 2013, 14 (04) : 418 - 424
  • [26] Prognostic factors in resectable pathological N2 disease of non-small cell lung cancer
    Hsieh, Chen-Ping
    Fu, Jui-Ying
    Liu, Yun-Hen
    Yang, Cheng-Ta
    Hsieh, Ming-Ju
    Tsai, Ying-Huang
    Wu, Yi-Cheng
    Wu, Ching-Yang
    BIOMEDICAL JOURNAL, 2015, 38 (04) : 329 - 335
  • [27] Survival Impact of Stations of Pathological Lymph Nodes in N2 Non-small Cell Lung Cancer in a French Hospital
    Clement-Duchene, Christelle
    Luc, Amandine
    Casse, Jean-Matthieu
    Vignaud, Jean-Michel
    Lacomme, Stephanie
    Anne, Valentine
    Siat, Joelle
    Menard, Olivier
    Martinet, Yves
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (05) : 1262 - 1268
  • [28] Surgical Resection of Non-Small Cell Lung Cancer with N2 Disease
    Donington, Jessica S.
    Pass, Harvey I.
    THORACIC SURGERY CLINICS, 2014, 24 (04) : 449 - +
  • [29] SURVIVAL FOLLOWING RESECTION OF CLINICALLY OCCULT N2 NON-SMALL-CELL LUNG-CANCER
    DALTON, R
    KELLER, S
    JOURNAL OF CARDIOVASCULAR SURGERY, 1994, 35 (06) : 13 - 17
  • [30] Surgery following neoadjuvant chemotherapy for non-small-cell lung cancer patients with unexpected persistent pathological N2 disease
    Hu, Xue-Fei
    Duan, Liang
    Jiang, Ge-Ning
    Chen, Chang
    Fei, Ke
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 4 (02) : 261 - 267